Abiomed Inc
ABMDDelisted Dec 22, 2022- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000815094
Abiomed Inc was delisted on Dec 22, 2022; its insiders filed their last Form 4 on Dec 27, 2022; 516 institutions reported holding it in 13F filings for Q3 2022, worth $10.6B in total; Maverick Capital was the only superinvestor holding it.
13F holders, Q3 2022
Institutional positions in Abiomed Inc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
ABMD is no longer listed, so this page shows Q3 2022. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 516
- +23 vs. Q2 2022
- Shares held
- 43.1M
- +491.9K (+1.2%) vs. Q2 2022
- Total value
- $10.6B
- +$37.7M (+0.4%) vs. Q2 2022
- New holders
- 55
- 189 more added
- Sold out
- 32
- 175 more reduced
4 institutions that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ABMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $381 |
| Q1 2026 | 2 | $381 |
| Q4 2025 | 2 | $381 |
| Q3 2025 | 2 | $381 |
| Q2 2025 | 2 | $381 |
| Q1 2025 | 2 | $381 |
| Q4 2024 | 2 | $381 |
| Q3 2024 | 2 | $381 |
| Q2 2024 | 2 | $381 |
| Q1 2024 | 2 | $381 |
| Q4 2023 | 2 | $381 |
| Q3 2023 | 2 | $381 |
| Q2 2023 | 2 | $381 |
| Q1 2023 | 3 | $1.50M |
| Q4 2022 | 9 | $4.62M |
| Q3 2022 | 516 | $10.6B |
| Q2 2022 | 497 | $10.5B |
| Q1 2022 | 499 | $14.0B |
| Q4 2021 | 496 | $15.1B |
| Q3 2021 | 499 | $13.4B |
| Q2 2021 | 475 | $13.0B |
| Q1 2021 | 488 | $13.2B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Abiomed Inc; share changes are against Q2 2022.